DURECT Corporation Doses First European Patient in Phase 2b AHFIRM Study of Larsucosterol(DUR-928) in Severe Alcohol-Associated Hepatitis

DURECT Corporation announced it dosed the first patient in the European Union as part of its AHFIRM randomized, double-blind, placebo-controlled, multi-center Phase IIb study to evaluate the safety and efficacy of larsucosterol in severe alcohol-associated hepatitis. patients.